

# Bone Marrow Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/B2D08922480FEN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: B2D08922480FEN

## Abstracts

The 7 major bone marrow failure markets are expected to exhibit a CAGR of 6.82% during 2024-2034.

The bone marrow failure market has been comprehensively analyzed in IMARC's new report titled "Bone Marrow Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bone marrow failure refers to a condition in which there's a decrease in the production of one or more types of blood cells. This disease can result in low counts of red blood cells that can cause fatigue, weakness, and shortness of breath. It can also lead to a decreased number of white blood cells, making patients more susceptible to infections, and a reduced level of platelets, increasing the tendency to bleed and bruise easily. Numerous other symptoms of the illness include pale skin, small red spots under the skin, an enlarged liver or spleen, etc. The diagnosis of bone marrow failure typically involves a thorough medical history review, clinical feature evaluation, and physical examination. The healthcare provider may also perform a flow cytometry technique that uses fluorescently labeled antibodies to analyze the characteristics of cells and determine the presence of specific markers associated with the disease. Furthermore, a bone marrow aspiration and biopsy are conducted to assess the cellularity and detect if there are any abnormalities in the formation of blood cells.

The increasing cases of inherited syndromes, which can damage and interfere with the normal functioning of the bone marrow, leading to inadequate production of blood cells, are primarily driving the bone marrow failure market. In addition to this, the rising prevalence of several risk factors, such as exposure to toxins and hazardous chemicals, vitamin deficiencies, viral infections, certain medications, etc., is also creating a positive

outlook for the market. Moreover, the widespread adoption of stem cell transplantation, which involves replacing the malfunctioning bone marrow with healthy tissues to restore normal blood cell production, is further bolstering the market growth. Apart from this, the inflating application of effective immunosuppressants, like anti-thymocyte globulin and cyclosporine, to help in reducing the activity of the immune system and decreasing inflammation in individuals suffering from the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of androgenic hormone therapy, since it can minimize the complications of the condition by stimulating erythropoiesis and promoting overall blood cell counts, is expected to drive the bone marrow failure market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the bone marrow failure market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bone marrow failure and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bone marrow failure market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the bone marrow failure market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the bone marrow failure market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bone marrow failure marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the bone marrow failure market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the bone marrow failure market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the bone marrow failure market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of bone marrow failure across the seven major markets?

What is the number of prevalent cases (2018-2034) of bone marrow failure by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of bone marrow failure by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with bone marrow failure across the seven major markets?

What is the size of the bone marrow failure patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of bone marrow failure?

What will be the growth rate of patients across the seven major markets?

### Bone Marrow Failure: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for bone marrow failure drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bone marrow failure market?

What are the key regulatory events related to the bone marrow failure market?

What is the structure of clinical trial landscape by status related to the bone marrow failure market?

What is the structure of clinical trial landscape by phase related to the bone marrow failure market?

What is the structure of clinical trial landscape by route of administration related to the bone marrow failure market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 BONE MARROW FAILURE - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 BONE MARROW FAILURE - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 BONE MARROW FAILURE - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 BONE MARROW FAILURE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 BONE MARROW FAILURE - UNMET NEEDS**

## **10 BONE MARROW FAILURE - KEY ENDPOINTS OF TREATMENT**

## **11 BONE MARROW FAILURE - MARKETED PRODUCTS**

- 11.1 List of Bone Marrow Failure Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 BONE MARROW FAILURE - PIPELINE DRUGS**

### 12.1 List of Bone Marrow Failure Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 EXG 34217 - Elixirgen

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 CK0801 - Cellenkos

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. BONE MARROW FAILURE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. BONE MARROW FAILURE – CLINICAL TRIAL LANDSCAPE 14.1 DRUGS BY STATUS**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 BONE MARROW FAILURE - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Bone Marrow Failure - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Bone Marrow Failure - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Bone Marrow Failure - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Bone Marrow Failure - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies(2024-2034)

#### 15.3.3 Bone Marrow Failure - Access and Reimbursement Overview

### 15.4 Market Scenario - Germany

#### 15.4.1 Bone Marrow Failure - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

#### 15.4.2 Bone Marrow Failure - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

#### 15.4.3 Bone Marrow Failure - Access and Reimbursement Overview

### 15.5 Market Scenario - France

#### 15.5.1 Bone Marrow Failure - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

#### 15.5.2 Bone Marrow Failure - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

#### 15.5.3 Bone Marrow Failure - Access and Reimbursement Overview

### 15.6 Market Scenario - United Kingdom

#### 15.6.1 Bone Marrow Failure - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

#### 15.6.2 Bone Marrow Failure - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

#### 15.6.3 Bone Marrow Failure - Access and Reimbursement Overview

### 15.7 Market Scenario - Italy

#### 15.7.1 Bone Marrow Failure - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast2024-2034)

#### 15.7.2 Bone Marrow Failure - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

- 15.7.3 Bone Marrow Failure - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Bone Marrow Failure - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Bone Marrow Failure - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Bone Marrow Failure - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Bone Marrow Failure - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Bone Marrow Failure - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Bone Marrow Failure - Access and Reimbursement Overview

## **16 BONE MARROW FAILURE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 BONE MARROW FAILURE MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 BONE MARROW FAILURE MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Bone Marrow Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/B2D08922480FEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B2D08922480FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

